1) National Collaborating Centre for Mental Health (UK) Psychosis and Schizophrenia in Adults: Treatment and Management. Updated Edition 2014. London: National Institute for Health and Care Excellence (UK); 2014.
2) McIlwain ME, Harrison J, Wheeler AJ, Russell BR. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2011;7:135-149.
4) McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
5) Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
6) Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 2009;23:957-965.
7) Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 2003;182:505-508.
9) Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012;22:165-182.
11) Wagner E, Lohrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmetation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance. J Psychopharmacol 2019;33:423-435.
12) Muscatello MRA, Bruno A, Fazio PD, Segura-Garcia C, Fandolfo G, Zoccali R. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opin Pharmacother 2014;15:2329-2345.
14) Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacology 2002;16:169-175.
15) Kang SH, Lee HW. Prescribing pattern of clozapine and clinical factors associated with discontinuation of clozapine. Korean J Schizophr Res 2019;22:1-7.
17) Chang JG, Roh DY, An SK, Cho HS, Kim CH. Antipsychotic polypharmacy in the treatment of patients with related psychosis at a university hostipal. Korean J Psychopharmacol 2013;24:69-75.
18) Yun JY, Lee JS, Kang SH, Nam BW, Lee SJ, Lee SH, et al. Korean treatment guideline on pharmacotherapy of co-existing symptoms and antipsychotics-related side effects in patients with schizophrenia. Korean J Schizophr Res 2019;22:21-33.
19) Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam BW, et al. Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms. Clin Psychopharmacol Neuroscience 2020;18:386-394.
22) Guinart D, Correll CU. Antipsychotic polypharmacy in schizophrenia: why not? J Clin Psychiatry 2020;83:3.
23) Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 2014;12:253.
24) Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. May 2014;17:33-37.
25) Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378.
27) Mao YM, Zhang MD. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat 2015;11:701-713.
28) Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016;173:876-886.